To assess the clinical relevance of ALDH1L1 expression in hormone receptor-positive breast cancer and its association with clinicopathologic features and survival outcomes.
Key Findings:
ALDH1L1 expression was higher in non-tumor tissues than in cancer tissues (p=0.0014 and p=0.0282 for two datasets).
Higher ALDH1L1 expression correlated with smaller tumor size, lower pT stage in luminal A and HER2+ subtypes, and lower nuclear grade in triple-negative breast cancer (p-values needed).
ALDH1L1 expression was associated with improved overall and disease-free survival, particularly in hormone receptor-positive subtypes (p=0.0049 and p=0.0441).
Interpretation:
Reduced ALDH1L1 expression is linked to aggressive clinicopathologic features and poorer survival in breast cancer, particularly in the luminal A subtype, highlighting its clinical significance.
Limitations:
The study's findings are based on specific cohorts from a single institution, which may limit generalizability and introduce potential biases.
Further research is needed to fully understand the mechanisms behind ALDH1L1 expression and its role in breast cancer.
Conclusion:
ALDH1L1 may serve as a subtype-specific favorable biomarker and potential therapeutic target in hormone receptor-positive breast cancer, warranting further investigation.
